| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
|
N Engl J Med
|
2009
|
18.03
|
|
2
|
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2011
|
13.10
|
|
3
|
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Eur Heart J
|
2011
|
10.52
|
|
4
|
Long-term use of ticagrelor in patients with prior myocardial infarction.
|
N Engl J Med
|
2015
|
8.69
|
|
5
|
Third universal definition of myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
8.59
|
|
6
|
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
|
N Engl J Med
|
2014
|
5.25
|
|
7
|
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2015
|
5.15
|
|
8
|
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
|
Lancet
|
2010
|
3.55
|
|
9
|
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
|
N Engl J Med
|
2011
|
3.20
|
|
10
|
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
|
Lancet
|
2010
|
2.98
|
|
11
|
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Atherosclerosis
|
2011
|
2.90
|
|
12
|
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
|
Circulation
|
2009
|
2.84
|
|
13
|
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
|
Circulation
|
2010
|
2.46
|
|
14
|
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
|
Thromb Haemost
|
2014
|
2.29
|
|
15
|
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Am Heart J
|
2009
|
2.23
|
|
16
|
[ESC/EAS Guidelines for the management of dyslipidaemias].
|
Rev Esp Cardiol
|
2011
|
2.21
|
|
17
|
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
|
Circulation
|
2013
|
2.03
|
|
18
|
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
|
J Am Coll Cardiol
|
2007
|
2.01
|
|
19
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
|
J Am Coll Cardiol
|
2010
|
2.00
|
|
20
|
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
|
Stroke
|
2013
|
1.99
|
|
21
|
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Eur Heart J
|
2011
|
1.98
|
|
22
|
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2010
|
1.96
|
|
23
|
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
|
Circulation
|
2012
|
1.84
|
|
24
|
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).
|
Eur Heart J
|
2014
|
1.81
|
|
25
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
26
|
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
|
Circ Cardiovasc Genet
|
2010
|
1.77
|
|
27
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
|
BMJ
|
2011
|
1.74
|
|
28
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
|
Circulation
|
2012
|
1.66
|
|
29
|
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
|
Circulation
|
2012
|
1.62
|
|
30
|
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Atherosclerosis
|
2011
|
1.51
|
|
31
|
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation.
|
Rev Esp Cardiol (Engl Ed)
|
2015
|
1.49
|
|
32
|
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
|
JACC Cardiovasc Interv
|
2013
|
1.46
|
|
33
|
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
|
CMAJ
|
2012
|
1.45
|
|
34
|
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
|
Value Health
|
2013
|
1.45
|
|
35
|
Clopidogrel resistance.
|
Catheter Cardiovasc Interv
|
2004
|
1.42
|
|
36
|
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
|
Platelets
|
2004
|
1.42
|
|
37
|
Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
|
Arterioscler Thromb Vasc Biol
|
2010
|
1.41
|
|
38
|
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Eur Heart J
|
2010
|
1.34
|
|
39
|
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2011
|
1.33
|
|
40
|
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
|
Circulation
|
2010
|
1.30
|
|
41
|
Antiplatelet agents for the treatment and prevention of atherothrombosis.
|
Eur Heart J
|
2011
|
1.23
|
|
42
|
Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor.
|
Thromb Haemost
|
2005
|
1.23
|
|
43
|
Update on lipids, inflammation and atherothrombosis.
|
Thromb Haemost
|
2011
|
1.16
|
|
44
|
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
|
Circulation
|
2011
|
1.13
|
|
45
|
Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease.
|
Thromb Haemost
|
2013
|
1.12
|
|
46
|
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Am Heart J
|
2012
|
0.96
|
|
47
|
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.96
|
|
48
|
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
|
Eur Heart J
|
2013
|
0.96
|
|
49
|
[ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)].
|
G Ital Cardiol (Rome)
|
2012
|
0.95
|
|
50
|
Response variability to P2Y12 receptor inhibitors: expectations and reality.
|
JACC Cardiovasc Interv
|
2013
|
0.94
|
|
51
|
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
|
J Am Coll Cardiol
|
2011
|
0.94
|
|
52
|
The role of platelets in inflammation.
|
Thromb Haemost
|
2015
|
0.92
|
|
53
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
|
Clin Chem
|
2011
|
0.90
|
|
54
|
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques.
|
PLoS One
|
2010
|
0.89
|
|
55
|
Effect of P2Y12 inhibitors on inflammation and immunity.
|
Thromb Haemost
|
2015
|
0.88
|
|
56
|
Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
|
Platelets
|
2006
|
0.88
|
|
57
|
Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?
|
Thromb Haemost
|
2014
|
0.87
|
|
58
|
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
|
Clin Pharmacokinet
|
2012
|
0.86
|
|
59
|
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
|
Am Heart J
|
2011
|
0.86
|
|
60
|
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
|
J Am Coll Cardiol
|
2012
|
0.84
|
|
61
|
Development and clinical use of prasugrel and ticagrelor.
|
Curr Pharm Des
|
2012
|
0.84
|
|
62
|
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2016
|
0.83
|
|
63
|
Platelet function testing in atherothrombotic disease.
|
Curr Pharm Des
|
2012
|
0.83
|
|
64
|
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
|
Clin Cardiol
|
2010
|
0.83
|
|
65
|
Antiplatelet therapy and vascular disease: an update.
|
Ther Adv Cardiovasc Dis
|
2010
|
0.83
|
|
66
|
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].
|
Kardiol Pol
|
2015
|
0.82
|
|
67
|
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).
|
Circ Cardiovasc Genet
|
2015
|
0.82
|
|
68
|
Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.
|
EuroIntervention
|
2013
|
0.81
|
|
69
|
Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention.
|
Curr Treat Options Cardiovasc Med
|
2012
|
0.81
|
|
70
|
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
|
Clin Chem
|
2013
|
0.81
|
|
71
|
Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes.
|
Thromb Haemost
|
2016
|
0.80
|
|
72
|
Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?
|
Pharmacol Ther
|
2010
|
0.80
|
|
73
|
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
|
Platelets
|
2005
|
0.80
|
|
74
|
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
|
Platelets
|
2008
|
0.80
|
|
75
|
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
|
Thromb Haemost
|
2014
|
0.80
|
|
76
|
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
|
Thromb Haemost
|
2014
|
0.79
|
|
77
|
P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
|
Thromb Haemost
|
2015
|
0.79
|
|
78
|
Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.
|
Platelets
|
2008
|
0.79
|
|
79
|
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
|
Platelets
|
2005
|
0.79
|
|
80
|
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
|
EuroIntervention
|
2015
|
0.79
|
|
81
|
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
|
Thromb Haemost
|
2006
|
0.78
|
|
82
|
Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function.
|
Thromb Haemost
|
2010
|
0.78
|
|
83
|
The right oral antithrombotics in acute coronary syndromes.
|
Lancet
|
2009
|
0.77
|
|
84
|
Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.
|
Platelets
|
2012
|
0.76
|
|
85
|
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].
|
G Ital Cardiol (Rome)
|
2016
|
0.76
|
|
86
|
The future of P2Y12 receptor antagonists.
|
Platelets
|
2015
|
0.76
|
|
87
|
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
|
Platelets
|
2013
|
0.76
|
|
88
|
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
|
Stroke
|
2013
|
0.75
|
|
89
|
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
|
Circulation
|
2014
|
0.75
|
|
90
|
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
|
Thromb Haemost
|
2013
|
0.75
|
|
91
|
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
92
|
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
|
Platelets
|
2014
|
0.75
|
|
93
|
Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery.
|
J Am Coll Cardiol
|
2011
|
0.75
|
|
94
|
Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period.
|
Platelets
|
2014
|
0.75
|
|
95
|
What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?
|
Diab Vasc Dis Res
|
2010
|
0.75
|
|
96
|
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
|
Int J Clin Pharmacol Ther
|
2017
|
0.75
|
|
97
|
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
|
Am J Med
|
2013
|
0.75
|
|
98
|
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
|
Am Heart J
|
2012
|
0.75
|
|
99
|
BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
|
Thromb Haemost
|
2016
|
0.75
|
|
100
|
Impact of presentation and transfer delays on complete ST segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial.
|
EuroIntervention
|
2017
|
0.75
|
|
101
|
Ticagrelor: from concept to clinical evaluation.
|
Biomark Med
|
2011
|
0.75
|
|
102
|
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes.
|
Int J Clin Pharmacol Ther
|
2016
|
0.75
|
|
103
|
Contemporary management of ST-segment elevation myocardial infarction.
|
Hosp Pract (1995)
|
2012
|
0.75
|
|
104
|
Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
|
J Cardiovasc Transl Res
|
2013
|
0.75
|